Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

Çetin M., Şahin S.

DRUG DELIVERY, cilt.23, sa.8, ss.2796-2805, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 8
  • Basım Tarihi: 2016
  • Doi Numarası: 10.3109/10717544.2015.1089957
  • Dergi Adı: DRUG DELIVERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2796-2805
  • Anahtar Kelimeler: Cancer, diabetes mellitus, metformin hydrochloride, microparticles, nanoparticles, IN-VITRO, BREAST-CANCER, FORMULATION, PHARMACOKINETICS, MICROSPHERES, MECHANISMS, TABLETS, OPTIMIZATION, COMBINATION, MANAGEMENT
  • Atatürk Üniversitesi Adresli: Evet

Özet

Context: Metformin hydrochloride is a biguanide derivative widely used for the treatment of type 2 diabetes, prescribed nearly to 120 million people worldwide. Metformin has a relatively low oral bioavailability (about 50-60%). Although the major effect of metformin is to decrease hepatic glucose output as an antihyperglycemic agent, its inhibitory effects on the proliferation of some cancer cells (e.g. prostate, breast, glioma cells) have been demonstrated in the cell culture studies. Development of novel formulation (e.g. microparticles, nanoparticles) strategies for metformin might be useful to improve its bioavailability, to reduce the dosing frequency, to decrease gastrointestinal side effects and toxicity and to be helpful for effective use of metformin in cancer treatment.